Vivos Therapeutics Stock Today
| VVOS Stock | USD 2.95 0.06 2.08% |
Performance4 of 100
| Odds Of DistressOver 81
|
Vivos Therapeutics is selling for under 2.95 as of the 22nd of November 2024; that is 2.08 percent increase since the beginning of the trading day. The stock's lowest day price was 2.8. Vivos Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Vivos Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 11th of December 2020 | Category Healthcare | Classification Health Care |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea , and snoring in adults. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. The company has 4.84 M outstanding shares of which 95.09 K shares are at this time shorted by private and institutional investors with about 0.66 trading days to cover. More on Vivos Therapeutics
Moving against Vivos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vivos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVivos Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vivos Therapeutics' financial leverage. It provides some insight into what part of Vivos Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vivos Therapeutics (VVOS) is traded on NASDAQ Exchange in USA. It is located in 7921 Southpark Plaza, Littleton, CO, United States, 80120 and employs 114 people. Vivos Therapeutics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.97 M. Vivos Therapeutics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 4.84 M outstanding shares of which 95.09 K shares are at this time shorted by private and institutional investors with about 0.66 trading days to cover.
Vivos Therapeutics currently holds about 17.83 M in cash with (11.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77.
Check Vivos Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Vivos Therapeutics is $13.97 Million. About 84.77 % of Vivos Therapeutics outstanding shares are held by general public with 1.51 (%) owned by insiders and only 13.72 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Vivos Ownership Details
Vivos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ronald Blue Trust, Inc. | 2024-09-30 | 160 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 136 | |
| Bank Of America Corp | 2024-06-30 | 103 | |
| Kozak & Associates, Inc. | 2024-09-30 | 49.0 | |
| Global Retirement Partners, Llc. | 2024-09-30 | 23.0 | |
| Td Waterhouse Canada Inc | 2024-06-30 | 12.0 | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 8.0 | |
| Royal Bank Of Canada | 2024-06-30 | 7.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Strategic Wealth Designers | 2024-09-30 | 100 K | |
| Omers Administration Corp | 2024-09-30 | 25 K |
Vivos Therapeutics Historical Income Statement
Vivos Stock Against Markets
Vivos Therapeutics Corporate Management
| RaeAnn Byrnes | CoFounder Services | Profile | |
| Kirk Huntsman | Chairman CoFounder | Profile | |
| Julie Gannon | Chief Relations | Profile | |
| Nicholas DeGennaro | Senior Division | Profile | |
| John Ballard | Senior Technology | Profile | |
| Ruth Hembree | Senior Services | Profile | |
| Todd Huntsman | CoFounder Technology | Profile |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.